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ABSTRACT
The algorithms included in most automated systems used for antimicrobial susceptibility testing (e.g.,
Vitek 2) consider that Escherichia coli isolates resistant to cefoxitin are AmpC-hyperproducers and,
consequently, resistant also to amoxycillin–clavulanate. However, a recent study revealed that 30% of
E. coli clinical isolates resistant to cefoxitin remained susceptible in vitro to amoxycillin–clavulanate. The
aim of the present study was to evaluate the in-vivo efficacy of amoxycillin–clavulanate in the treatment
of an experimental model of pneumonia, using two clonally related isolates (with identical repetitive
extragenic palindromic sequence (REP)-PCR patterns) of AmpC-non-hyperproducing and OmpF-
lacking E. coli (Ec985 and Ec571) that were resistant to cefoxitin and susceptible to cefotaxime and
amoxycillin–clavulanate. MICs were determined using a microdilution technique, and in-vitro
bactericidal activity was tested using time-kill assays. The in-vivo efficacy of amoxycillin, amoxycil-
lin–clavulanate and cefotaxime against both isolates was tested in a murine pneumonia model using
immunocompetent C57BL ⁄ 6 mice. Ec571 (a TEM-1 ⁄ 2 producer) was resistant to amoxycillin, whereas
Ec985 (a TEM-1 ⁄ 2 non-producer) was susceptible. Amoxycillin, amoxycillin–clavulanate and cefotaxime
were bactericidal for Ec985, and amoxycillin–clavulanate and cefotaxime were bactericidal for Ec571 at
different concentrations and time-points, as determined using time-kill assays. Treatment with
amoxycillin, amoxycillin–clavulanate and cefotaxime reduced the bacterial lung concentration of
Ec985 compared with non-treated controls (p <0.05), whereas amoxycillin–clavulanate and cefotaxime
showed efficacy against Ec571 when compared with the control and amoxycillin groups (p <0.05).
Regardless of the exact underlying mechanism(s) of resistance, amoxycillin–clavulanate was effective in
the experimental murine model in the treatment of pneumonia caused by AmpC-non-hyperproducing
strains of E. coli resistant to cefoxitin.
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INTRODUCTION
Infections caused by Escherichia coli are frequently
treated with b-lactams and fluoroquinolones.
Susceptibility of E. coli to b-lactams is variable and
may be compromised by b-lactamase production
and ⁄ or decreased outer-membrane permeability
mediated by porin loss [1]. Clinical isolates of
E. coli that hyperproduce plasmid- or chromo-
some-encoded AmpC-type b-lactamases are
usually resistant to cefoxitin, oxyimino-cephalo-
sporins (i.e., cefotaxime, ceftriaxone and ceftazi-
dime) and amoxycillin–clavulanate, but remain
susceptible to zwitterionic cephalosporins (i.e.,
cefepime and cefpirome) and carbapenems. In
contrast, isolates of E. coli producing extended-
spectrum b-lactamases and porins usually
show susceptibility in vitro to cefoxitin, amoxy-
cillin–clavulanate and carbapenems. These two
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phenotypes of resistance to b-lactams (AmpC and
extended-spectrum b-lactamase production) may
be more complex if an additional mechanism of
resistance, e.g., porin loss, is present in the same
isolate of E. coli.
Most automated systems used for antimicrobial
susceptibility testing include an expert system or
algorithm that is used to interpret phenotypes of
resistance ⁄ susceptibility to antimicrobial agents.
Some of these algorithms (e.g., that used by the
Vitek 2 system) consider that isolates of E. coli
resistant to cefoxitin and susceptible to amoxycil-
lin–clavulanate are AmpC hyperproducers, and
consequently, these isolates are assumed to be
resistant to amoxycillin–clavulanate. However, a
recent study observed that c. 30% of clinical
isolates of E. coli resistant to cefoxitin remained
susceptible in vitro to amoxycillin–clavulanate [2].
The aims of the present study were to investi-
gate the mechanisms of resistance to b-lactams in
clinical isolates of E. coli resistant to cefoxitin and
susceptible to amoxycillin–clavulanate, and to
evaluate the in-vivo efficacy of amoxycillin–
clavulanate in the treatment of pneumonia caused
by E. coli with this phenotype of resistance in an
experimental murine model.
MATERIALS AND METHODS
Bacteria
Two isolates of E. coli (Ec985 and Ec571), obtained originally
from urinary tract infections at the Department of Microbiol-
ogy, University Hospital Virgen Macarena, Seville, Spain, were
used for the study. E. coli ATCC 25922 and E. coli ATCC 35218
(for antimicrobial susceptibility testing), and Micrococcus luteus
ATCC 9341 (for the bioassay method) were used as standard
reference strains.
Ec985 and Ec571 were identified using the Vitek 2 system
(bioMe´rieux, Marcy l’Etoile, France) and were shown to be
clonally related by repetitive extragenic palindromic sequence
PCR (REP-PCR) analysis using primers REP-1 (5¢-IIIGCGCC
GICATCAGGC) and REP-2 (5¢-ACGTCTTATCAGGCCTAC)
as described previously [3]. The criteria used to select
these two isolates were their identical REP-PCR and antimi-
crobial susceptibility patterns (determined using the Vitek 2
system), except for their susceptibility to amoxycillin (see
below).
Antimicrobial susceptibilities
MICs of amoxycillin, cefoxitin, cefotaxime (Sigma-Aldrich, St
Louis, MO, USA), cefepime (Bristol-Myers Squibb, Madrid,
Spain), imipenem (Merck Sharp & Dohme, Madrid, Spain),
meropenem (Zeneca Farma, Madrid, Spain) and amoxycillin–
clavulanate (SmithKline Beecham, Madrid, Spain,) were deter-
mined by a microdilution assay according to CLSI guidelines
[4]. MICs of cefoxitin were also determined in combination
with a fixed concentration (4 mg ⁄L) of clavulanate or BRL
42715 (SmithKline Beecham).
Time-kill assays
The bactericidal activities of amoxycillin, amoxycillin–clavula-
nate and cefotaxime against Ec985 and Ec571 were determined
in Mueller–Hinton broth (Becton Dickinson, Cockeysville,
MD, USA) using a time-kill assay [5] with an inoculum of
5 · 105 CFU ⁄mL and concentrations of amoxycillin, amoxycil-
lin–clavulanate and cefotaxime that were equal to 1·, 2· and 4·
the respective MICs and the Cmax (maximal serum concentra-
tion reached in mice). Tubes with no antimicrobial agent were
inoculated with each isolate and used as growth controls.
Bacterial counts were determined at 0, 2, 4, 8 and 24 h after
incubation (37C without shaking) by plating 100 lL at the
indicated times on sheep blood 5% v ⁄v agar plates in dupli-
cate. An antibiotic was considered to be bactericidal if a ‡3 log10
decrease in CFU ⁄mL was observed in comparison with the
initial inoculum.
b-Lactamase characterisation
Isoelectric points (pIs) of b-lactamases obtained from crude
supernatants were determined by isoelectric focusing using
the Phast-System (ampholyte pI range, 3.5–9; Pharmacia, Sant
Cugat del Valle´s, Spain).
Hydrolysis of cephaloridine (b-lactamase activity) was
determined spectrophotometrically using crude extracts.
Hydrolysis of cefoxitin was also determined by the Hodge
test, modified by replacing the imipenem disk with a cefoxitin
(30-lg) disk (Becton Dickinson) [6]. Agar plates were inocu-
lated with a suspension (adjusted to a 0.5· McFarland
standard) of E. coli ATCC 25922 (indicator strain of cefoxitin
hydrolysis).
Mutations in the promoter ⁄ attenuator region of the ampC
gene were identified as described previously [7]. PCR products
were sequenced in both directions using a Big Dye Terminator
v.3.0 sequencing kit (Applied Biosystems, Foster City, CA,
USA). Sequence analysis was performed using a 3700 DNA
Analyzer (Applied Biosystems).
Analysis of outer-membrane protein (OMP) profiles
OMPs were analysed by SDS-PAGE (acrylamide 12% w ⁄v and
6 M urea in the running gel), using cell envelopes of sonicated
cells as described previously [8].
Mice
Immunocompetent specific pathogen-free C57BL ⁄ 6 young
female mice, weighing 16–20 g, were supplied by the Uni-
versidad de Sevilla’s animal facility. Animals were housed in
regulation cages with free access to food and water. The study
was approved by the local Ethical and Clinical Research
Committee (approval no. 10 ⁄ 02).
Drug pharmacokinetics
The plasma levels of each drug were determined after
the administration of single doses to non-infected mice.
Amoxycillin (GlaxoSmithKline, Madrid, Spain), amoxycillin–
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clavulanate (GlaxoSmithKline) and cefotaxime (Aventis
Pharma, Madrid, Spain) were administered intramuscularly.
The dosages used were: 50 ⁄ 5 and 80 ⁄ 8 mg ⁄ kg for amoxycillin–
clavulanate, 50 and 80 mg ⁄ kg for cefotaxime, and 50 mg ⁄ kg
for amoxycillin. Blood was obtained after 10, 15, 30, 60, 90, 120
and 150 min from an incision in the periorbital plexus of
anaesthetised mice, using groups of three mice for each time-
point. The drug concentrations in serum were measured by a
bioassay method, using M. luteus ATCC 9341 as the indicator
strain. The maximum plasma concentration (Cmax; mg ⁄L) and
the elimination half-life (t1 ⁄ 2; h) were calculated using the
PKCALC program [9]. The time during which the plasma
concentration remained above the MIC (T>MIC, h) was
estimated by extrapolation from the regression line of the
plasma elimination phase [10], and the percentage of the T>MIC
between doses was calculated.
Mouse pneumonia model
The model described by Esposito and Pennington [11],
modified by Rodrı´guez-Herna´ndez et al. [12], was used to
produce pneumonia in mice. This model was evaluated
independently for both Ec985 and Ec571. Mice were infected
by intra-tracheal instillation, using 50 lL of a suspension of
5 · 108 CFU ⁄mL in the exponential growth phase, diluted to
50% v ⁄v with porcine mucin (M-2378; Sigma-Aldrich). The
experiments were designed to evaluate the decrease in the
lung bacterial concentrations after treatments with amoxycil-
lin, amoxycillin–clavulanate and cefotaxime. Taking into
account the T>MIC results, the doses and intervals of intra-
muscular administration were: amoxycillin, 50 mg ⁄ kg every
2 h, with five doses; amoxycillin–clavulanate, 50 ⁄ 5 mg ⁄ kg
every 2 h, with five doses; and cefotaxime, 50 mg ⁄ kg every
3 h, with four doses. Control groups without treatment were
used for comparisons.
Antimicrobial agents were dissolved in sterile saline
(NaCl 0.9% w ⁄v) immediately before administration. The
first dose of antimicrobial agent was administered 4 h after
the bacterial inoculation (0 h). Beginning at 0 h, immediately
before each treatment time-point, three treated and three
control mice were killed using an intraperitoneal dose of
sodium thiopental 5% w ⁄v (Braun Medical, Barcelona,
Spain). The lungs were immediately removed aseptically,
weighed, and finally processed for quantitative cultures after
homogenisation (Stomacher 8; Tekmar Co., Cincinnati, OH,
USA) in 2 mL of sterile saline. After ten-fold dilution,
aliquots of 100 lL were plated on sheep blood 5% v ⁄v agar
and incubated for 24 h at 37C. Sterile cultures were
considered to indicate £1 log10 CFU ⁄g of lung (i.e., the
sensitivity limit of the method is equal to 1 CFU). The
results were expressed as means ± SDs of the log10 CFU ⁄ g
of lung values.
Histopathological studies
Lung samples were processed for pathological studies from
five mice of each group. The lungs were fixed with formalde-
hyde 10% v ⁄v, embedded in paraffin, and cut into 4-lm-thick
sections. The slices included all the pulmonary lobes, for
subsequent study by optical microscopy, and were processed
using standard methods for haematoxylin–eosin, periodic acid
Schiff’s, Gram’s, Masson’s Trichromic and silver reticulin
stains.
Statistical analysis
The CFU ⁄g values for lung tissue among the control, amoxy-
cillin and amoxycillin–clavulanate groups were evaluated by
analysis of variance (ANOVA) and post-hoc tests (Dunnett and
Tukey tests) for multiple comparisons. The CFU ⁄g values of
lung tissue for the control and cefotaxime groups were
analysed using the paired Student’s t-test. Differences were
considered to be significant when p values were <0.05. SPSS
v.12.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical
tests.
RESULTS
In-vitro studies
The two E. coli isolates studied were resistant to
cefoxitin (MIC 128 mg ⁄L) and susceptible to
amoxycillin–clavulanate (MIC 8 mg ⁄L), the
broad-spectrum cephalosporins cefotaxime, ceft-
azidime and cefepime (MICs £0.5 mg ⁄L), and the
carbapenems imipenem and meropenem
(MICs £0.06 mg ⁄L). Strain Ec571 was resistant to
amoxycillin (MIC 512 mg ⁄L) whereas Ec985 was
susceptible (MIC 8 mg ⁄L). The MICs of cefoxitin
for both Ec571 and Ec985 decreased from 128 to
64 mg ⁄L in the presence of clavulanic acid or
BRL 42715.
Two b-lactamase bands (pIs ‡9 and 5.4, respec-
tively), were observed for Ec571, while Ec985 only
had the pI ‡9 band. The b-lactamase activity of
the pI ‡9 band was inhibited by cloxacillin, but
not by clavulanate. In contrast, the pI 5.4 band
was inhibited by clavulanate, but not by cloxacil-
lin. These bands were consistent with the pres-
ence of AmpC and TEM-1 ⁄ 2, respectively.
Specific b-lactamase activity (mU ⁄mg) was 56.7
for Ec571 and 6.9 for Ec985. Hydrolysis of
cefoxitin was not detected spectrophotometrically
or with the microbiological method used.
The ampC regulatory region of both isolates
contained a series of point mutations that were
unrelated toAmpChyperproduction:)88 (C ﬁ T),
)82 (A ﬁ G), )56 (G ﬁ C), )18 (G ﬁ A), )1
(C ﬁ T) and +58 (C ﬁ T).
The OMP profiles of the two strains were
characterised by the presence of OmpC and
OmpA porins, and the absence of OmpF porin.
As summarised in Table 1, the three antimicro-
bial agents were bactericidal for Ec985 at all
concentrations at different time-points, and there
was no regrowth. For Ec571 (Table 2) the three
antimicrobial agents were bactericidal at all con-
centrations at different time-points, with the
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exception of the Cmax of amoxycillin, which was
lower than the MIC; moreover, with amoxycillin
there was regrowth, beginning at 8 h, at all
concentrations tested, and with amoxycillin–cla-
vulanate and cefotaxime at the concentration
equivalent to the MIC.
Pharmacokinetics and pharmacodynamics
The serum pharmacokinetic and pharmacody-
namic parameters for each antimicrobial agent
are summarised in Table 3. For each antimicrobial
agent, a dose of 50 mg ⁄kg was chosen for the treat-
ment of the pneumonia because of the similarity of
the T>MIC with both 50 and 80 mg ⁄ kg.
Histopathological analysis
Mice inoculated with either E. coli isolate showed
alterations compatible with acute pneumonia,
with acute diffuse and ⁄ or focal inflammation in
all lobes, with mild-to-severe inflammatory infil-
tration of polymorphonuclear cells, sometimes
forming segmentary abscesses, and mild-to-
moderate infiltration of alveolar macrophages.
Gram-negative bacterial colonies, necrosis and
alveolar haemorrhagic areas were also observed.
Bacterial clearance from lungs
The bacterial concentrations in the lungs of the
different treatment groups are summarised in
Tables 4 and 5. For Ec985, treatment with amoxy-
cillin, amoxycillin–clavulanate and cefotaxime
significantly reduced the bacterial concentra-
tion in the lungs (p <0.05). The highest rate of
bacterial clearance for Ec985 was observed with
amoxycillin–clavulanate ()3.81 log10 CFU ⁄g at
8 h). In comparison with the control groups, the
differences in bacterial counts with the three
treatments were also significant (p <0.05). No
differences among the treatment groups were
revealed.
For Ec571, treatment with amoxycillin–clavula-
nate and cefotaxime reduced the bacterial
concentration in the lungs (p <0.05), with no
significant difference between the two agents.
However, amoxycillin was ineffective in reducing
the number of bacteria. Again, the highest rate of
bacterial clearance was observed with amoxy-
cillin–clavulanate ()3.40 log10 CFU ⁄ g at 8 h).
DISCUSSION
The two clonally related isolates of E. coli included
in the present study produced an AmpC b-lactam-
ase (pI ‡9), but did not hyperproduce it, based on
the high level of susceptibility of both strains
to cefotaxime and ceftazidime, the low level of
b-lactamase activity detected, and the absence of
Table 1. Time-kill assays with amoxycillin (AMX), amoxy-
cillin–clavulanate (AMC) and cefotaxime (CTX) against
Escherichia coli strain Ec985
Antimicrobial agent
Log10 CFU ⁄mL at time (h)
0 2 4 8 24
None (growth control) 6.1 6.7 8.3 9.3 10.3
AMX (n · MIC) 1· 6.1 5.7 3.7 2.9 1.3
2· 6.1 5.3 3.7 2.9 1.0
4· 6.1 4.2 3.7 2.4 1.0
Cmax 6.1 2.9 3.7 2.9 1.0
AMC (n · MIC) 1· 6.1 5.7 5.0 3.2 <1
2· 6.1 5.7 3.6 2.8 <1
4· 6.1 4.8 3.0 2.5 <1
Cmax 6.1 4.4 2.5 2.5 <1
CTX (n · MIC) 1· 6.1 5.7 4.8 3.5 2.7
2· 6.1 5.3 4.4 5.0 2.4
4· 6.1 5.1 4.1 4.4 2.0
Cmax 6.1 4.4 3.7 <1 <1
Table 2. Time-kill assays with amoxycillin (AMX), amoxy-
cillin–clavulanate (AMC) and cefotaxime (CTX) against
Escherichia coli strain Ec571
Antimicrobial agent
Log10 CFU ⁄mL at time (h)
0 2 4 8 24
None (growth control) 6.2 6.8 8.1 9.6 11.3
AMX (n · MIC) 1· 6.2 3.0 3.0 6.1 11.2
2· 6.2 <1 <1 3.6 11.0
4· 6.2 <1 <1 2.7 10.6
Cmax 6.2 6.1 7.9 9.4 11.3
AMC (n · MIC) 1· 6.2 3.7 2.0 2.1 5.6
2· 6.2 <1 1.8 <1 <1
4· 6.2 <1 1.6 <1 <1
Cmax 6.2 <1 1.3 <1 <1
CTX (n · MIC) 1· 6.2 3.0 3.5 3.2 5.8
2· 6.2 <1 3.0 2.0 <1
4· 6.2 <1 2.9 1.6 <1
Cmax 6.2 <1 1.6 <1 <1
Table 3. Pharmacokinetic and pharmacodynamic para-
meters of amoxycillin (AMX), amoxycillin–clavulanate
(AMC) and cefotaxime (CTX) in non-infected mice
Agent Dosage (mg ⁄kg) MIC (mg ⁄L) Cmax (mg ⁄L) t1 ⁄ 2 (h) T>MIC (h)
AMX 50 8a 15.1 0.28 0.48
AMC 50 ⁄ 5b 8c 17.9 0.40 0.55
AMC 80 ⁄ 8b 8c 16.7 0.38 0.49
CTX 50 £0.5c 57.6 0.27 1.89
CTX 80 £0.5c 76.7 0.20 1.57
aIsolate Ec985.
bAMC doses.
cIsolates Ec985 and Ec571.
T>MIC: time with serum concentrations above the MIC.
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hydrolysis of cefoxitin. Additionally, most of the
point mutations detected in the regulatory region
of ampC have been reported previously to be
unassociated with hyperproduction of AmpC [7].
Although the effect of mutation at position –56 has
not been studied previously, the low level of
b-lactamase activity in both isolates suggests that
it may not have a significant role in the hyperpro-
duction ofAmpC. Previous studies have suggested
that resistance of AmpC-hyperproducing isolates
of E. coli to cefoxitin may be achieved by the loss of
the OmpF porin [8]. Since the two isolates of E. coli
in the present study lacked OmpF, but were not
hyperproducers of AmpC, it is possible that addi-
tional mechanisms (e.g., overproduction of efflux
pumps or alterations in penicillin-binding pro-
teins) might combine with the lack of OmpF to
produce resistance.
Whatever the actual underlying mechanism of
resistance, amoxycillin, amoxycillin–clavulanate
and cefotaxime had a significant bactericidal
effect in vitro against the isolate (Ec985) that did
not produce TEM-1 ⁄ 2 b-lactamase, suggesting
that these antimicrobial agents could also be
active in vivo. For the isolate producing TEM-1 ⁄ 2
(Ec571), amoxycillin–clavulanate and cefotaxime
were also bactericidal in vitro, indicating that
production of TEM-1 ⁄ 2 has no effect in vitro on
the activity of these antimicrobial agents.
The study also investigated whether amoxycil-
lin–clavulanate could be used to treat infections
caused by E. coli with the novel phenotype of
resistance to cefoxitin in the absence of AmpC
overproduction. The experimental model of pneu-
monia in immunocompetent mice used in this
study is simple to develop and yields highly
reproducible results [12]. The main limitation of
this model is that E. coli is not among the most
common causes of pneumonia. However, E. coli
causes 4.3% of cases of severe community-
acquired pneumonia, with a mortality rate of
35% [13], and also causes late-onset nosocomial
pneumonia [14].
The in-vivo experiments revealed that amoxy-
cillin–clavulanate is as effective as cefotaxime in
the treatment of pneumonia caused by E. coli with
the novel resistance phenotype. The same degree
of efficacy was observed despite the higher T>MIC
between doses of cefotaxime (63%) and amoxy-
cillin–clavulanate (27%). Amoxycillin, with a
T>MIC (24%) similar to that of amoxycillin–clavul-
anate, was effective against pneumonia caused by
Ec985 (susceptible to amoxycillin), but not against
that caused by Ec571 (resistant to amoxycillin).
b-Lactams have a time-dependent bactericidal
effect and, in order to maximise their activity, the
T>MIC should remain close to 40% [15]. The T>MIC
for amoxycillin and amoxycillin–clavulanate in
the present study was lower (c. 25% between
doses) because of the choice, for ethical reasons,
of a minimum interval between doses of 2 h.
However, no reduction in efficacy was observed
for either antimicrobial agent in the treatment of
experimental pneumonia caused by isolates
showing in-vitro susceptibility.
Table 4. Bacterial concentrations
(mean log10 CFU ⁄ g of tissue ± SD)
in the lungs of mice infected with
Escherichia coli isolates Ec985 and
Ec571, either without treatment
(Control) or treated with amoxycillin
(AMX) or amoxycillin–clavulanate
(AMC)
Time (h)
0 2 4 6 8 10
Ec985
Control 8.94 ± 0.39 9.91 ± 0.97 8.40 ± 1.51 8.26 ± 1.33 8.47 ± 0.53 8.99 ± 0.57
AMX 8.94 ± 0.39 8.33 ± 0.25 6.91 ± 0.46a 7.12 ± 0.05a 7.01 ± 0.19a 6.82 ± 0.41a
AMC 8.94 ± 0.39 7.84 ± 0.34a 7.13 ± 0.34a 5.40 ± 0.18a,c 5.13 ± 0.57a,b,c 6.34 ± 0.13a,b
Ec571
Control 8.43 ± 0.83 9.10 ± 0.07 8.46 ± 0.69 8.57 ± 0.65 9.30 ± 0.38 9.72 ± 0.09
AMX 8.43 ± 0.83 9.29 ± 0.19 8.20 ± 0.09 8.83 ± 0.30 9.43 ± 0.12 8.81 ± 1.57
AMC 8.43 ± 0.83 6.99 ± 0.52b,c 6.30 ± 0.06a,c 5.83 ± 0.04a,b,c 5.03 ± 0.03a,b,c 5.54 ± 0.40a,b
ap <0.05 in intra-group comparisons with respect to bacterial concentrations at time 0 h.
bp <0.05 compared with control group.
cp <0.05 compared with AMX group.
Table 5. Bacterial concentrations (mean log10 CFU ⁄ g of
tissue ± SD) in the lungs of mice infected with Escherichia
coli isolates Ec985 and Ec571, either without treatment
(Control) or treated with cefotaxime (CTX)
Time (h)
0 3 6 9 12
Ec985
Control 8.79 ± 0.48 9.30 ± 0.06 8.26 ± 1.33 8.94 ± 0.17 9.16 ± 1.44
CTX 8.79 ± 0.48 7.67 ± 0.23a,b 6.62 ± 0.38a 5.88 ± 0.37a,b 6.12 ± 0.28a,b
Ec571
Control 8.43 ± 0.91 9.07 ± 0.22 8.57 ± 0.65 9.53 ± 0.13 7.83 ± 1.79
CTX 8.43 ± 0.91 6.63 ± 0.03a,b 5.81 ± 0.13a,b 5.58 ± 0.53a,b 5.64 ± 0.17a
ap <0.05 in intra-group comparisons with respect to bacterial concentration at time
0 h.
bp <0.05 compared with control group.
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In conclusion, these results indicate that isolates
of E. coli resistant to cefoxitin and susceptible to
amoxycillin–clavulanate should be checked for
AmpC hyperproduction to avoid erroneous
reporting of resistance to amoxycillin–clavulanate.
It appears that loss of porin OmpF, but not
hyperproduction of AmpC, is partially responsi-
ble for the resistance pattern of such isolates.
Finally, although the in-vivo experiments sug-
gested that amoxycillin–clavulanate could be
used for the treatment of infections caused by
E. coli with this resistance phenotype, addi-
tional in-vivo experiments should be performed
before definitive clinical recommendations can be
made.
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